NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
We assessed Form 483 issued by U.S. Food and Drug Administration after inspection at Cipla Ltd.’s Goa site.
Form 483 highlights issues largely related to testing methods, monitoring environmental conditions, cleaning/disinfections and root cause analysis. Considering the observations, we await classification of the inspection to incorporate potential business from key products like g-Abraxane. Nonetheless, Cipla remains on track to file complex products in respiratory, peptides and differentiated product category.
We estimate a 12% earnings computer annual growth rate backed by 12%/7% sales CAGRs in DF/US generics and a 120bp margin expansion over FY24-26.
Considering a healthy pipeline of niche products and superior execution in the branded generics segment, we Cipla on SOTP basis (24 times 12 month forward earnings and net present of Rs 30 for g-Revlimid) to arrive at our target price of Rs 1,700. We maintain Buy rating on the stock.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR